Conflicts of interest None declared.
The impact of changes in clinical severity on psychiatric morbidity in patients with psoriasis: a follow-up study
Article first published online: 11 JUL 2007
British Journal of Dermatology
Volume 157, Issue 3, pages 508–513, September 2007
How to Cite
Sampogna, F., Tabolli, S., Abeni, D. and the IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) investigators (2007), The impact of changes in clinical severity on psychiatric morbidity in patients with psoriasis: a follow-up study. British Journal of Dermatology, 157: 508–513. doi: 10.1111/j.1365-2133.2007.08071.x
A complete list of the IMPROVE investigators who contributed to this study appears in the Acknowledgments.
- Issue published online: 10 AUG 2007
- Article first published online: 11 JUL 2007
- Accepted for publication 3 May 2006
- quality of life;
Background Psoriasis has a strong impact on quality of life and is correlated to psychopathological states. It is important to investigate the effect of clinical changes on psychological status.
Objectives To analyse the extent of clinical change and its effect on the presence of psychiatric morbidity in a group of patients with psoriasis.
Methods All eligible adults hospitalized with psoriasis in a dermatological hospital (February 2000–February 2002) were given the self-administered Psoriasis Area and Severity Index (SAPASI) to assess clinical severity, the 12-item General Health Questionnaire (GHQ-12) to detect patients with psychological problems (defined as ‘cases’) and the Skindex-29 to evaluate symptoms. The same questionnaires were completed by the patients a month after hospital discharge.
Results In our population of 414 patients, the incidence of GHQ cases becoming noncases was correlated with the SAPASI percentage improvement, ranging from 17·6% in patients with SAPASI worsened or unchanged at follow-up, to 68·2% in patients with clearance of psoriasis. Also, the proportion of patients who became GHQ noncases was much higher in patients with improvement of ≥ 50% in symptoms, compared with patients with no improvement or worsening (70% vs. 32%, respectively). In a multivariate model the possible determinants of the passage from GHQ case to noncase were: SAPASI improvement, symptom improvement, no localization on the face, and gender (i.e. women were less likely to improve psychologically).
Conclusions The improvement in clinical severity and symptoms was associated with a decreased frequency of psychiatric disturbance. However, dermatologists should be aware that even in the presence of vast clinical improvement patients may still substantially suffer psychologically.